Belgian diagnostics company Biocartis Group NV and Singpore’s A*STAR ETPL have kicked off development of a multimodal breast cancer assay designed to guide therapy selection in personalised medicine.
Small molecule cancer drug developer 4SC AG (Planegg-Martinsried, Germany) has completed a capital increase fueling development of its clinical programmes for resminostat, 4SC-202 and 4SC-208
German biotech company Biontech AG has published positive clinical results for its individualised cancer vaccine Ivac mutanome in patients with late-stage melanoma.
Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventure’s Health for Life Capital investment vehicle.
Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.
British pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)’s artificial intelligence (AI)-driven drug discovery platform.
![Follicular lymphoma is the most common type of slow-growing blood cancer. [Credit: E. Oricchio et al., Science Translational Medicine (2017)]](https://european-biotechnology.com/wp-content/uploads/2024/04/FL_oricchio1HR-180x180.jpg "FL_oricchio1HR.jpg")
Swiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy.
Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.
European venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, the company’s app analyses the individual microbiome to predict blood sugar responses to thousands of different foods.
Venture Capitalist Biogeneration Ventures has exceeded the target size of its life sciences fund BGV III through investments from the European Investment Bank’s InnovFin Equity Facility and the Dutch Venture Initiative II.